Eliquis

Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:
Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up
Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up
Fierce Pharma
Bayer
JNJ
Xarelto
bloodthinners
Bristol-Myers Squibb
Pfizer
Eliquis
Flag link:
J&J snaps up key label expansion for Xarelto
J&J snaps up key label expansion for Xarelto
Biopharma Dive
JNJ
Xarelto
bloodthinners
Eliquis
Janssen
Bayer
Flag link:
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive
Fierce Pharma
Pfizer
Bristol-Myers Squibb
JNJ
Eliquis
Xarelto
Warfarin
bloodthinners
Flag link:
How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
Biopharma Dive
Bristol-Myers Squibb
Pfizer
Warfarin
real world evidence
RWE
bloodthinners
Eliquis
Flag link:
Bristol-Myers calls on real-world evidence to unseat warfarin
Bristol-Myers calls on real-world evidence to unseat warfarin
Biopharma Dive
Bristol-Myers Squibb
Warfarin
Eliquis
Pfizer
bloodthinners
Flag link:
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Flag link:
After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO
After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO
Fierce Pharma
Bristol-Myers Squibb
Eliquis
Pharma CEOs
Giovanni Caforio
Pfizer
JPMHC 2018
Flag link:
Bristol-Myers, Pfizer continue to build case for Eliquis
Bristol-Myers, Pfizer continue to build case for Eliquis
BioPharma Dive
Bristol-Myers Squibb
Pfizer
Eliquis
blood thinners
Flag link:
Bristol-Myers, Pfizer come up victorious in 20 more Eliquis bleeding cases
Bristol-Myers, Pfizer come up victorious in 20 more Eliquis bleeding cases
Fierce Pharma
Bristol-Myers Squibb
Pfizer
Eliquis
bloodthinners
Flag link:
Bristol-Myers Squibb recalls mislabeled Eliquis medications
Bristol-Myers Squibb recalls mislabeled Eliquis medications
BioPharma Dive
Bristol-Myers Squibb
Eliquis
recalls
labeling
Flag link:
BMS and Pfizer file 16 Eliquis patent lawsuits to waylay generic makers
BMS and Pfizer file 16 Eliquis patent lawsuits to waylay generic makers
Fierce Pharma
Bristol-Myers Squibb
Pfizer
patents
Eliquis
patent lawsuits
generics
bloodthinners
Flag link:
Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin
Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin
BioPharma Dive
Bristol-Myers Squibb
Pfizer
Eliquis
bloodthinners
Warfarin
Flag link:
Many at risk for stroke don’t get anti-clotting drugs
Many at risk for stroke don’t get anti-clotting drugs
Reuters
stroke
atrial fibrillation
Pradaxa
Xarelto
Eliquis
bloodthinners
Flag link:
Pfizer's 3 Fastest-Growing Drugs
Pfizer's 3 Fastest-Growing Drugs
Motley Fool
Pfizer
Ibrance
Eliquis
Xeljanz
Flag link:
Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16
Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16
Market Realist
Bristol-Myers Squibb
Eliquis
blood thinners
Flag link:
Eliquis Proving to Be a Major Growth Driver for Pfizer This Year
Eliquis Proving to Be a Major Growth Driver for Pfizer This Year
Market Realist
Eliquis
bloodthinners
Pfizer
Flag link:
Why Eliquis Matters to Bristol-Myers Squibb’s Cardiovascular Business
Why Eliquis Matters to Bristol-Myers Squibb’s Cardiovascular Business
Yahoo/Market Realist
Bristol-Myers Squibb
Eliquis
Flag link:
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa
Fierce Pharma Marketing
bloodthinners
Bristol-Myers Squibb
Eliquis
Xarelto
Pradaxa
Bayer
Pfizer
JNJ
Boehringer Ingelheim
Flag link:
4 Blockbuster Drugs Whose Sales Could Easily Double
4 Blockbuster Drugs Whose Sales Could Easily Double
Motley Fool
Xtandi
Medivation
Astellas
Eliquis
Pfizer
Bristol-Myers Squibb
Revlimid
Celgene
Invokana
JNJ
Flag link:

Pages